February 01, 2023
Alexander Spira, MD, PhD, FACP, discusses osimertinib-relapsed disease and its sensitivity to EGFR or MET inhibition.
January 30, 2023
The phase 2/3 EVEREST study of zorifertinib for patients with advanced EGFR-mutated non–small cell lung cancer with central nervous system metastases elicited significant efficacy and comparable safety to other tyrosine kinase inhibitors in this indication.
January 17, 2023
Based on the acceptance of its investigational new drug application by the FDA, the safety and tolerability of HT-001 will be evaluated in the phase 2a CLEER of patients with rash and skin disorders associated with EGFR inhibitor therapy.
January 16, 2023
During a Targeted Oncology case-based roundtable event, Zofia Piotrowska, MD, MHS, discussed molecular testing for actionable mutations and recommended treatments for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
January 05, 2023
Andreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.
December 16, 2022
Andreas Saltos, MD, discusses the key discoveries from a phase 1/1B trial of erlotinib and binimetinib in EGFR- and KRAS-mutated non–small cell lung cancer.
December 15, 2022
After participating in a Case-Based Roundtable event led by Gavitt Woodward, MD, M. Sheila Donnelly, MD, spoke with Targeted Oncology about the patients with lung cancer she treats.
December 05, 2022
During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.
November 25, 2022
Tepotinib plus gefitinib led to improvements in progression-free survival and overall survival in patients with EGFR-mutant non–small cell lung cancer.
November 21, 2022
During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.